Introduction Insmed is a worldwide biopharmaceutical corporation dedicated to improving the lives of patients with severe and uncommon illnesses. Their flagship product, ARIKAYCE, has been approved in the US for treating Mycobacterium avium complex (MAC) lung disease in adults who have limited or no other treatment options. |
Disease Domain | Count |
---|---|
Infectious Diseases | 3 |
Nervous System Diseases | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Unknown | 1 |
Gene therapy | 1 |
Target |
Mechanism 30S subunit inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date01 Jan 1981 |
Target |
Mechanism DPP-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PGI2 receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Apr 2024 |
Sponsor / Collaborator |
Start Date27 Dec 2023 |
Sponsor / Collaborator |
Start Date30 Oct 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Amikacin Sulfate ( 30S subunit ) | Mycobacterium Infections, Nontuberculous More | Approved |
Treprostinil palmitil ( PGI2 receptor ) | Pulmonary Arterial Hypertension More | Phase 3 Clinical |
Brensocatib ( DPP-1 ) | COVID-19 More | Phase 3 |
RV-94 ( Peptidoglycan ) | Staphylococcal Infections More | Preclinical |
INS-1201 | Muscular Dystrophy, Duchenne More | Preclinical |